| Popis: |
Biljana Ivanovska Adjievska,1 Salih Boskurt,1 Nikola Orovcanec,2 Vesna Dimovska-Jordanova3 1Department for Posterior Segment, European Eye Hospital, Skopje, Republic of Macedonia; 2Department for Medical Statistics, Institute for Epidemiology and Medical Statistics, Medical Faculty, Skopje, Republic of Macedonia; 3Department for Retinal Diseases, University Clinic for Eyes Diseases, St Cyril and Methodius University, Skopje, Republic of Macedonia Aim: We aimed to evaluate the 1-year efficacy and safety of low-frequency intravitreal bevacizumab in the treatment of macular edema due to retinal vein occlusions (RVOs).Methods: The study comprised an interventional prospective study of patients with macular edema due to central retinal vein occlusion (CRVO) or branch retinal vein occlusion, followed for 12months. Treatment-naïve patients with reduced best-corrected visual acuity (BCVA) and central macular thickness (CMT) of at least 250µm received intravitreal injection of bevacizumab. After 1month, BCVA and optical coherence tomography (OCT) images of the macula were recorded. In patients with 0.3 log of the minimum angle of resolution [logMAR] units) with average number of injections of 1.98. Improvement of mean BCVA in CRVO was significant (P=0.001) from baseline (1.2±0.95 logMAR units) to 1year (0.75±0.6 logMAR units). Significant improvement of mean BCVA (P |
